Summary of Scenti Biosciences Conference Call Company Overview - **Company**: Scenti Biosciences - **Industry**: Biotechnology - **Focus**: Development of cell and gene therapies for incurable diseases using a synthetic biology platform called GeneCircuits [1][2] Core Technology and Product Development - **Technology**: Logic gating technology allows targeting of previously untreatable cancers, enhancing precision and control in therapy [3][4] - **Lead Program**: Santi 202, targeting relapsed/refractory Acute Myeloid Leukemia (AML) and related cancers, currently in early-stage clinical trials [4][5] - **Manufacturing**: Scalable off-the-shelf manufacturing streamlines treatment for patients [5] Clinical Data and Efficacy - **Clinical Results**: Positive data reported at AACR 2025 meeting, with five patients achieving overall response rate (ORR) and four achieving complete response [15] - **Durability**: Longest-term patient response lasted over eight months, indicating potential for outpatient use [14][15] - **Patient Population**: AML affects over 20,000 newly diagnosed patients annually, with a 60% relapse rate within 12 months [10] Mechanism of Action - **Logic Gates**: Designed to differentiate between cancerous and healthy cells, minimizing toxicity [7][8] - **Cell Engineering**: Utilizes natural killer (NK) cells genetically modified to express proteins targeting AML cells while protecting healthy cells [11][12] - **Key Proteins**: Includes activating CAR (ACAR) targeting CD33 and FLT3, and an inhibitory CAR that protects healthy cells [12][13] Clinical Trial Design - **Phase One Trial**: Multicenter, multinational study assessing two dose levels (1 billion and 1.5 billion CAR positive NK cells) [16][17] - **Dosing Schedule**: Patients receive multiple doses, with assessments for response at 28 days [18] Safety and Tolerability - **Patient Monitoring**: Recovery of healthy blood cell counts observed post-treatment, indicating maintenance of healthy bone marrow [22][23] - **Toxicity Management**: Logic gating technology aims to reduce toxicity associated with traditional therapies [7][8] Future Directions - **Expansion Plans**: Focus on increasing patient numbers and showcasing the efficacy of logic gating technology [30][31] - **Broader Applications**: Potential to apply logic gating technology to solid tumors and other cancer types [25][28] Competitive Landscape - **Differentiation**: Scenti's approach is agnostic to genetic mutations, providing a complementary mechanism to existing therapies targeting genetic mutations in AML [32] - **Comparison with CAR T**: NK cells are preferred for AML due to their rapid action and safety profile, while T cells may be more suitable for solid tumors [33][34] Conclusion - **Outlook**: Scenti Biosciences is positioned to advance its lead program Santi 202 and explore broader applications of its technology in the oncology space, with ongoing clinical trials and promising early results [27][28]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [3] Upcoming Event - Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio, will present at the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on May 29, 2025, at 2:40 PM ET [1][2] Technology and Pipeline - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [3] - The Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications extending beyond oncology [3]

Core Insights - Senti Biosciences, Inc. has received an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) for achieving clinical study enrollment milestones, bringing the total received from an $8 million grant to $7.4 million [1] - The company is developing SENTI-202, a first-in-class Logic Gated off-the-shelf CAR-NK cell therapy aimed at treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [1][3] - Preliminary results from the ongoing Phase 1 trial of SENTI-202 indicate it is well-tolerated, with no dose-limiting toxicities reported and a recommended Phase 2 dose identified as 1.5 x 10^9 CAR NK cells [4] Company Overview - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, which aims to enhance precision and control in targeting cancer cells while sparing healthy cells [5] - The company's pipeline includes cell therapies engineered with Gene Circuits to address challenging liquid and solid tumor indications, demonstrating preclinical efficacy in both NK and T cells [5] Clinical Development - SENTI-202 is currently in a Phase 1 clinical trial (NCT06325748) and has shown promising preliminary results, with two out of three patients in the recommended Phase 2 dose cohort achieving a composite Complete Remission (cCR) [4] - The trial data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 supports the Logic Gate mechanism of action, with four out of four cCR patients being Measurable Residual Disease Negative (MRD-) [4]

LOS ANGELES, May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ: SNTI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Senti announced in a press release issued on April 28, 2025, that "enrollmen ...

Senti Biosciences (SNTI) 2025 Conference May 08, 2025 01:00 PM ET Speaker0 Are you ready to kick it off? Yeah. Whenever you guys wanna do. Speaker1 Okay. Welcome back to the Citizens Life Science Conference. My name is Silvan Turca, and I'm a senior analyst covering precision medicines. And now it's my pleasure to introduce Sandi Biosciences. Presenting will be Tim Liu, CEO and cofounder, and Jay Cross, CFO. Thank you so much for coming and joining us today. Speaker0 Well, thanks a lot, Silvan. Appreciate t ...

Core Insights - Senti Biosciences, Inc. is advancing its lead asset, SENTI-202, a first-in-class off-the-shelf CAR NK cell therapy targeting hematologic malignancies like AML and MDS [2][3] - The company has reported positive preliminary results from a Phase 1 clinical trial, indicating SENTI-202 is well-tolerated with no dose-limiting toxicities [4] - The mechanism of action for SENTI-202 involves a novel gene circuit that selectively kills leukemia cells while sparing healthy hematopoietic stem cells [3][8] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][6] - The company's pipeline includes engineered cell therapies targeting both liquid and solid tumors, leveraging synthetic biology for enhanced precision and control [6] Clinical Trial Details - SENTI-202 is currently in a Phase 1 trial enrolling adult patients with relapsed/refractory CD33 and/or FLT3-expressing hematologic malignancies [3] - The preliminary recommended Phase 2 dose (RP2D) for SENTI-202 was identified as 1.5 x 10 CAR NK cells administered on Days 0, 7, and 14 in 28-day cycles following lymphodepleting chemotherapy [4] - In the preliminary RP2D cohort, 2 of 3 patients achieved a composite Complete Remission (cCR), and 5 of 7 evaluable patients achieved an overall response rate (ORR) [4] Mechanism of Action - SENTI-202 utilizes a Logic Gated gene circuit to activate CAR targeting CD33 and/or FLT3, which are expressed in approximately 95% of AML patients [8] - The therapy protects healthy hematopoietic stem and progenitor cells (HSC/HSPCs) from off-tumor effects through an inhibitory CAR targeting Endomucin (EMCN) [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from ___to___ Commission File Number 001-40440 Senti Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

Core Insights - Senti Biosciences, Inc. presented positive Phase 1 data for its lead program SENTI-202 at the AACR Annual Meeting, indicating potential as a treatment for Acute Myeloid Leukemia (AML) with 4 out of 7 patients achieving composite Complete Remission (cCR) [1][3][4] - The company reported financial results for Q1 2025, showing a net loss of $14.1 million, with cash and cash equivalents of approximately $33.8 million as of March 31, 2025 [9][14] Clinical Data Highlights - SENTI-202 was well tolerated with no dose-limiting toxicities, and the preliminary recommended Phase 2 dose (RP2D) was identified as 1.5 x 10 CAR NK cells administered on Days 0, 7, and 14 in 28-day cycles [4] - All 4 patients who achieved cCR were measurable residual disease (MRD) negative, and responses have been maintained for follow-ups ranging from 4+ to 8+ months [1][4] - The ongoing enrollment in the Phase 1 study aims to confirm the RP2D and expand into disease-specific cohorts [1][3] Corporate Developments - The company is advancing its Logic-Gated cell therapy approach, which may have applications in both liquid and solid tumors, providing multiple pipeline expansion opportunities [1][2] - Senti Bio has joined the Webull Corporate Connect Service platform to enhance communication with shareholders and increase market visibility [5] Financial Overview - Research and development expenses for Q1 2025 were $9.3 million, an increase from $8.8 million in Q1 2024, primarily due to higher external services costs [9][14] - General and administrative expenses decreased to $7.1 million in Q1 2025 from $7.5 million in Q1 2024 [9][14] - The total operating expenses for the quarter were $16.4 million, slightly up from $16.3 million in the same period last year [9][14]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A due to observed dose limiting toxicities [2] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a decline of 27.2%, closing at $3.64 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and corporate misconduct [3] - The firm has a track record of recovering significant damages for class members, highlighting its expertise in handling such cases [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share on the same day [3] Group 2: Legal Actions - Pomerantz LLP is actively seeking claims from investors of Senti Biosciences, indicating a potential class action lawsuit [1][2] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [4]